CATALYST PHARMACEUTICAL PARTNERS, INC. Form 8-K

February 14, 2013

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

## **CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): February 11, 2013

## CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

**Delaware** (State or other jurisdiction

001-33057 (Commission 76-0837053 (I.R.S. Employer

of incorporation) File Number) Identification No.)

## Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K


### 355 Alhambra Circle

**Suite 1500** 

Coral Gables, Florida 33134
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: (305) 529-2522

### Not Applicable

Former Name or Former address, if changed since last report



- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

### Item 7.01 Regulation FD Disclosure

On February 11, 2013, the Company posted on its website the presentation materials from the Company s presentation at the 1<sup>th</sup> Annual BIO CEO & Investor Conference, held at the Waldorf Astoria Hotel in New York City, New York. The presentation is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including the presentation attached as Exhibit 99.1 hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities under that Section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing or document.

#### Item 8.01 Other Events

On February 11, 2013, the Company issued a press release updating the market on the status of the research and development pipeline for its product candidates Firdapse , CPP-115 and CPP-109. The press release is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

- (c) Exhibits
- 99.1 Information posted on Company s website on February 11, 2013
- 99.2 Press Release issued by the Company on February 11, 2013

## Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Alicia Grande Alicia Grande Vice President, Treasurer and CFO

Dated: February 11, 2013